Enterprise Value
-41.86M
Cash
100.7M
Avg Qtr Burn
-13.12M
Short % of Float
10.94%
Insider Ownership
0.53%
Institutional Own.
44.30%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ME-344 (Mitochondrial Inhibitor) Details Cancer, Solid tumor/s, Colorectal cancer | Phase 1b Data readout | |
Voruciclib (CDK Inhibitor) Details B-cell malignancies, Acute myeloid leukemia, Cancer | Phase 1b Data readout | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details Follicular lymphoma | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued |